

**Abstract**

The present invention relates to a novel antibody-based targeting drug – an energized fusion protein Fv-LDP-AE with anti-angiogenic activity, potent cancer cell killing activity and anti-cancer therapeutic efficacy, method for producing said agent, and use thereof in manufacture of an anti-cancer medicament.